Acorda share price development?

Discussion in 'Acorda Therapeutics' started by anonymous, May 24, 2018 at 1:40 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Investing in equity is all about dividend and/or share price development.

    Taking into account the company's current situation (Ampyra, Inbrija, rest of the pipeline etc), where do we see Acorda share price in say 2 or 5 years from now!?
     

  2. anonymous

    anonymous Guest

    Without a buyer—-flat

    With a buyer—maybe $35-$38
     
  3. anonymous

    anonymous Guest

    Unfortunately, neither Hindman nor Blank have taken an interest in building a pipeline.

    Both were sleeping at their desks dreaming that Toz was going to be a winner and Inbrija was a sure approval

    You know the story: Toz is dead due to safety, and Inbrija got a CRL

    Too bad for us the shareholders that Dr Cohen and the BoD didn't whip these two executive into shape.

    If Inbrija gets approved, stock may hit 28-29 on the news, then after that, a painful slow uptake as a pipeline is built. History repeats itself.
     
  4. anonymous

    anonymous Guest

    what a pessimist you are... my financial advisor is bullish and in 5 yrs easily $200-250. Inbrija is a ballbuster pipeline product ..

    With a near term sale yes your numbers look about right
     
  5. anonymous

    anonymous Guest

    We’ve heard your BS before. Your “advisor” seems to be the outlier and might have a bit of a crack problem if they think an inhaled LD is going to bring any company to a $200-$250 level.

    Maybe Inbrija is a ballbuster as you say for those that have to promote it. It sure as hell isnt a blockbuster!
     
  6. anonymous

    anonymous Guest

    There will be a mass exodus in the field soon.
    No faith and the word on The Street is that Ampyra has NO chance of winning and that IF Inbrija gets approved, ACOR stock will rise a small percent enough to be on the hopping block. There is active BD movement to sell.
     
  7. anonymous

    anonymous Guest

    previous court ruling),

    Ref today's news, I see things differently.

    Assuming Inbrija gets approved both in the US and EU (reasonably good chance), the share price will see a good jump, and Ampyra will carry at least a residual value for a few years against the generics.

    I foresee a 30-40+ price tag.

    I think I'll top up by another 50k.
     
  8. anonymous

    anonymous Guest

    You are way too pessimistic. My financial adviser says 200-300 within 5 yrs. Bulk up 50k is not that much, Beware the idiots who predict 25per share. They are dickheads!!
     
  9. anonymous

    anonymous Guest

    Re yesterday's and today's positive move, I'm very glad I topped up by another 50k :)

    Current share price is well below my average investment price, so any increase means just a thicker icing on my cake!

    Acordians, work hard and push both Inbrija applications (US & EU) through, and you will make many people (including myself) very happy :)
     
  10. anonymous

    anonymous Guest

    You really don’t have anything else to occupy your time do you?

    Let’s play along with your little charade. So you are up a buck on ACOR when the whole sector is up. You would have been up 4x this amount putting your money in REGN. Over the period you have been up $60 on GWPH and $90 on SAGE.

    Congrats on your $1 gain Tiger.
     
  11. anonymous

    anonymous Guest

    I refuse to invest in companies that impose glass ceiling constraints !! ACOR has the most liberal promotion practices (imho) in pharma. A great company with enlightened leaders and rank&file..
     
  12. anonymous

    anonymous Guest

    You are absolutely spot on!

    Indeed, I do have a lot of time for whatever I might fancy doing, and more importantly, I have a lot of money to do whatever I might fancy doing :)

    Anyway, I wish you a great day!
     
  13. anonymous

    anonymous Guest

    Your post is an insult to all ACOR investors...I just read this chain and am baffled by the stupidity of the negative posts like yours. Makes me wonder if I should pull out of this stock, although only have 250 shares.
     
  14. anonymous

    anonymous Guest

    We all like TV and music
     
  15. anonymous

    anonymous Guest

    Go be offended somewhere else.

    ACORs flat stock and poor management is an insult to investors.
     
  16. anonymous

    anonymous Guest

    F YOU. ..MANAGEMENT is top notch. We need a competent field team!!
     
  17. anonymous

    anonymous Guest

    My all favorite show is the Twilight Zone

    :p
     
  18. anonymous

    anonymous Guest

    mine is Price is Right